Integrilin trials

Drug Information available for: Eptifibatide. FDA Resources. Arms and Interventions. Intra-coronary injection, weight based, of eptifibatide. Intra-coronary injection, based on weight, of eptifibatide. Intra-coronary injection, weight based, of normal saline. Outcome Measures. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. Michael Gibson, M. More Information. Layout table for additonal information Responsible Party: C. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

ST-Elevation Myocardial Infarction. Drug Information available for: Heparin Heparin sodium Eptifibatide. FDA Resources. Arms and Interventions. Standard treatment daily doses of low molecular weight heparin.

Outcome Measures. Primary Outcome Measures : Change in platelet count from baseline to 72 hours post treatment [ Time Frame: 11 bloodsamples over 7 days ] Will be from pre-study drug administration until 7 days. Followed longer if not discharged from the ICU at day 7. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Inclusion Criteria: At least 18 years of age AND Suspected or proven bacterial pneumonia requiring administration of antibiotics: Clinical diagnosis of pneumonia, i.

Low-molecular-weight heparin within 12 hours prophylactic doses permitted. Thrombolytic therapy within 3 days before the study catheter clearance doses permitted. Antithrombin III with dose greater than 10, U within 12 hours before the study.

Protein C within 24 hours of the study. Previous diagnosed condition that might mimic or complicate the course and evaluation of the infectious disease process severe bronchiectasis, lung abcess or empyema, aspiration pneumonia, active tuberculosis, pulmonary malignancy, cystic fibrosis, severe chronic interstitial pneumonia, COPD or other forms of chronic lung disease requiring home oxygen treatment or resulting in chronic CO2 retention, , etc.

Patient not expected to survive more than 30 days because of uncorrectable medical or surgical condition other than sepsis Patient with acute or chronic renal failure requiring dialysis renal failure without need for dialysis permitted. Patient with hematological malignancies of any kind Patients who have undergone transplantation of bone marrow, liver, pancreas, heart, lung, or bowel kidney transplant permitted Patient has known hypercoagulable condition: APC resistance Hereditary protein C, protein S, or antithrombin III deficiency Anticardiolipin or antiphospholipid antibody Lupus anticoagulant Homocysteinemia Recent or highly suspected pulmonary embolism or deep venous thrombosis within 3 months Patients with known congenital hypocoagulable diseases Patient with known AIDS Patient with known primary pulmonary hypertension.

Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Among patients with ST elevation MI, treatment with combination therapy of eptifibatide and half-dose TNK compared with full dose TNK monotherapy was associated with a nonsignificant trend toward higher rates of TIMI grade 3 flow, but a trend toward higher rates of major hemorrhage.

It has been hypothesized that the lack of mortality benefit may be due to only small improvements in epicardial flow pooled average 6. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction. J Am Coll Cardiol ;